{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T13:10:09Z","timestamp":1792674609312,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T00:00:00Z","timestamp":1675987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1007\/s40121-023-00762-9","type":"journal-article","created":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T19:59:51Z","timestamp":1676059191000},"page":"891-917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["The Use and Effectiveness of Ceftazidime\u2013Avibactam in Real-World Clinical Practice: EZTEAM Study"],"prefix":"10.1007","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03923426","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alex","family":"Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Montravers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galina","family":"Klyasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Daikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paurus","family":"Irani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Chambers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efim","family":"Basin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Gaborit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kourbeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Menichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Teresa","family":"Perez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marisa","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Trompa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Verma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Lavinea N.","family":"de Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudie","family":"Charbonneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,10]]},"reference":[{"issue":"9761","key":"762_CR1","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S0140-6736(10)61458-4","volume":"377","author":"B Allegranzi","year":"2011","unstructured":"Allegranzi B, Bagheri Nejad S, Combescure C, et al. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011;377(9761):228\u201341.","journal-title":"Lancet"},{"key":"762_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1775","volume":"338","author":"DW Bates","year":"2009","unstructured":"Bates DW, Larizgoitia I, Prasopa-Plaizier N, Jha AK. Global priorities for patient safety research. BMJ. 2009;338: b1775.","journal-title":"BMJ"},{"key":"762_CR3","doi-asserted-by":"publisher","unstructured":"Zarb P, Coignard B, Griskeviciene J, et al. The European Centre for Disease Prevention and Control (ECDC) pilot point prevalence survey of healthcare-associated infections and antimicrobial use. Euro Surveill. 2012. https:\/\/doi.org\/10.2807\/ese.17.46.20316-en.","DOI":"10.2807\/ese.17.46.20316-en"},{"key":"762_CR4","unstructured":"World Health Organizations. Annual epidemiological report on communicable disease in Europe. 2008. https:\/\/ecdc.europa.eu\/sites\/portal\/files\/media\/en\/publications\/Publications\/0812_SUR_Annual_Epidemiological_Report_2008.pdf. Accessed 22 Feb 2018."},{"key":"762_CR5","unstructured":"Annual epidemiological report Reporting on 2011 surveillance data and 2012 epidemic intelligence data. 2013. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/media\/en\/publications\/Publications\/annual-epidemiological-report-2013.pdf. Accessed 21 Oct 2021."},{"key":"762_CR6","unstructured":"Healthcare associated infections (HAI): point prevalence survey, England. 2016. https:\/\/www.gov.uk\/government\/publications\/healthcare-associated-infections-hcai-point-prevalence-survey-england. Accessed 21 Oct 2021."},{"key":"762_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ijid.2019.06.016","volume":"86","author":"R Huerta-Guti\u00e9rrez","year":"2019","unstructured":"Huerta-Guti\u00e9rrez R, Braga L, Camacho-Ortiz A, et al. One-day point prevalence of healthcare-associated infections and antimicrobial use in four countries in Latin America. Int J Infect Dis. 2019;86:157\u201366.","journal-title":"Int J Infect Dis"},{"issue":"3","key":"762_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4103\/0974-777X.68531","volume":"2","author":"D Rawat","year":"2010","unstructured":"Rawat D, Nair D. Extended-spectrum beta-lactamases in Gram negative bacteria. J Glob Infect Dis. 2010;2(3):263\u201374.","journal-title":"J Glob Infect Dis"},{"issue":"2","key":"762_CR9","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cmi.2017.07.014","volume":"24","author":"M N\u00fa\u00f1ez-N\u00fa\u00f1ez","year":"2018","unstructured":"N\u00fa\u00f1ez-N\u00fa\u00f1ez M, Navarro MD, Palomo V, et al. The methodology of surveillance for antimicrobial resistance and healthcare-associated infections in Europe (SUSPIRE): a systematic review of publicly available information. Clin Microbiol Infect. 2018;24(2):105\u20139.","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"762_CR10","first-page":"11","volume":"5","author":"S Patolia","year":"2018","unstructured":"Patolia S, Abate G, Patel N, Patolia S, Frey S. Risk factors and outcomes for multidrug-resistant Gram-negative bacilli bacteremia. Ther Adv Infect Dis. 2018;5(1):11\u20138.","journal-title":"Ther Adv Infect Dis"},{"key":"762_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jhin.2021.09.021","volume":"119","author":"TL Lin","year":"2022","unstructured":"Lin TL, Chang PH, Chen IL, et al. Risk factors and mortality associated with multi-drug-resistant Gram-negative bacterial infection in adult patients following abdominal surgery. J Hosp Infect. 2022;119:22\u201332.","journal-title":"J Hosp Infect"},{"issue":"10","key":"762_CR12","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1038\/nrurol.2015.199","volume":"12","author":"HM Zowawi","year":"2015","unstructured":"Zowawi HM, Harris PN, Roberts MJ, et al. The emerging threat of multidrug-resistant Gram-negative bacteria in urology. Nat Rev Urol. 2015;12(10):570\u201384.","journal-title":"Nat Rev Urol"},{"issue":"3","key":"762_CR13","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2165\/11533040-000000000-00000","volume":"70","author":"JD Pitout","year":"2010","unstructured":"Pitout JD. Infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae: changing epidemiology and drug treatment choices. Drugs. 2010;70(3):313\u201333.","journal-title":"Drugs"},{"issue":"5","key":"762_CR14","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/j.1469-0691.2012.03821.x","volume":"18","author":"R Cant\u00f3n","year":"2012","unstructured":"Cant\u00f3n R, Ak\u00f3va M, Carmeli Y, et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect. 2012;18(5):413\u201331.","journal-title":"Clin Microbiol Infect"},{"key":"762_CR15","unstructured":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics. 2017. http:\/\/remed.org\/wp-content\/uploads\/2017\/03\/lobal-priority-list-of-antibiotic-resistant-bacteria-2017.pdf. Accessed 26 Oct 2021."},{"issue":"6","key":"762_CR16","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/s40265-017-0725-1","volume":"77","author":"D Wong","year":"2017","unstructured":"Wong D, van Duin D. Novel beta-lactamase inhibitors: unlocking their potential in therapy. Drugs. 2017;77(6):615\u201328.","journal-title":"Drugs"},{"key":"762_CR17","unstructured":"European Medical Association. Zavicefta\u00ae Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/zavicefta-epar-product-information_en.pdf. Accessed 28 Apr 2022."},{"issue":"4","key":"762_CR18","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1007\/s40121-021-00506-7","volume":"10","author":"JE Mazuski","year":"2021","unstructured":"Mazuski JE, Wagenlehner F, Torres A, et al. Clinical and microbiological outcomes of ceftazidime\u2013avibactam treatment in adults with gram-negative bacteremia: a subset analysis from the phase 3 clinical trial program. Infect Dis Ther. 2021;10(4):2399\u2013414.","journal-title":"Infect Dis Ther"},{"issue":"6","key":"762_CR19","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1517\/14656566.2016.1145658","volume":"17","author":"F Perez","year":"2016","unstructured":"Perez F, El Chakhtoura NG, Papp-Wallace KM, Wilson BM, Bonomo RA. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply \u201cprecision medicine\u201d to antimicrobial chemotherapy? Expert Opin Pharmacother. 2016;17(6):761\u201381.","journal-title":"Expert Opin Pharmacother"},{"key":"762_CR20","doi-asserted-by":"crossref","unstructured":"Jorgensen SCJ, Trinh TD, Zasowski EJ, et al. Real-world experience with ceftazidime\u2013avibactam for multidrug-resistant Gram-negative bacterial infections. Open Forum Infect Dis. 2019;6(12):ofz 522.","DOI":"10.1093\/ofid\/ofz522"},{"key":"762_CR21","unstructured":"Calvo-Garc\u00eda A, Ibanez Zurriaga MD, Ram\u00edrez Herr\u00e1iz E, P\u00e9rez Ab\u00e1nades M, S\u00e1ez B\u00e9jar C, Morell Baladr\u00f3n A. Ceftazidime\u2013avibactam: effectiveness and safety in the clinical practice. A third hospital level experience. Rev OFIL\u00b7ILAPHAR 2020;32(1):52\u201362."},{"key":"762_CR22","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/cid\/ciw133","volume":"62","author":"JE Mazuski","year":"2016","unstructured":"Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidimeavibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis. 2016;62:1380\u20139.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"762_CR23","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","volume":"10","author":"A Soriano","year":"2021","unstructured":"Soriano A, Carmeli Y, Omrani AS, Moore LSP, Tawadrous M, Irani P. Ceftazidime\u2013avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review. Infect Dis Ther. 2021;10(4):1989\u20132034.","journal-title":"Infect Dis Ther"},{"key":"762_CR24","doi-asserted-by":"crossref","unstructured":"Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime\u2013avibactam use for Klebsiella pneumoniae carbapenemase-producing K.\u00a0pneumoniae infections: a retrospective observational multicenter study. Clin Infect Dis. 2021;73(9):1664\u20131676.","DOI":"10.1093\/cid\/ciab176"},{"issue":"2","key":"762_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ijantimicag.2018.04.001","volume":"52","author":"RE Mendes","year":"2018","unstructured":"Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK. Molecular beta-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime\u2013avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: efficacies analysed against susceptible and resistant subsets. Int J Antimicrob Agents. 2018;52(2):287\u201392.","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"762_CR26","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","volume":"18","author":"A Torres","year":"2018","unstructured":"Torres A, Zhong N, Pachl J, et al. Ceftazidime\u2013avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285\u201395.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"762_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Y Carmeli","year":"2016","unstructured":"Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime\u2013avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661\u201373.","journal-title":"Lancet Infect Dis"},{"key":"762_CR28","first-page":"483","volume":"10","author":"AC Gales","year":"2022","unstructured":"Gales AC, Carmargo LFA, Cuba GT, et al. A review of real-world use of ceftazidime\u2013avibactam for multidrug-resistant gram-negative bacterial infections. J Infect Dis Ther. 2022;10:483.","journal-title":"J Infect Dis Ther"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00762-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-023-00762-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-023-00762-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T03:42:04Z","timestamp":1678938124000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-023-00762-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,10]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1007\/s40121-023-00762-9","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,10]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}